Showing results (1-10 of 22) with videos related to
Sort By:
Pageof 3
Expert Opinion on Biological Therapy|July 23, 2004
Using antibodies in tumour immunotherapyBirgit C Schultes, Christopher F NicodemusExpert Opinion on Biological Therapy|February 21, 2007
Role of monoclonal antibodies in tumor-specific immunityChristopher F Nicodemus, L Mary Smith, Birgit C SchultesExpert Review of Vaccines|August 12, 2003
Immunomodulation with antibodies: clinical application in ovarian cancer and other malignanciesChristopher F Nicodemus, Birgit C Schultes, Brian L HamiltonJournal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 14, 2003
Biologic and immunologic therapies for ovarian cancerJonathan S Berek, Birgit C Schultes, Christopher F NicodemusAmerican Journal of Obstetrics and Gynecology|July 16, 2003
Immune responses to murine monoclonal antibody-B43.13 correlate with prolonged survival of women with recurrent ovarian cancerVolker J Möbus, Richard P Baum, Marcus Bolle, et al.Gynecologic Oncology|August 7, 2004
CA125- and tumor-specific T-cell responses correlate with prolonged survival in oregovomab-treated recurrent ovarian cancer patientsAlan N Gordon, Birgit C Schultes, Holly Gallion, et al.Cancer Immunology, Immunotherapy : CII|December 1, 2011
Targeting HER2/neu with a fully human IgE to harness the allergic reaction against cancer cellsTracy R Daniels, Richard K Leuchter, Rafaela Quintero, et al.Immunotherapy|August 29, 2015
Antibody-based immunotherapy of solid cancers: progress and possibilitiesChristopher F NicodemusJournal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 1, 2004
Randomized, placebo-controlled study of oregovomab for consolidation of clinical remission in patients with advanced ovarian cancerJonathan S Berek, Peyton T Taylor, Alan Gordon, et al.Journal of Immunological Methods|September 13, 2003
Monitoring of immune responses to CA125 with an IFN-gamma ELISPOT assayBirgit C Schultes, Theresa L WhitesidePageof 3